Moleculin Biotech (MBRX)
(Delayed Data from NSDQ)
$4.32 USD
-0.14 (-3.14%)
Updated Jun 7, 2024 03:59 PM ET
After-Market: $4.32 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Moleculin Biotech, Inc. [MBRX]
Reports for Purchase
Showing records 101 - 120 ( 162 total )
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Shows Antiviral Activity of WP1096 - WP1097 in HIV, Dengue Fever - Zika
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
WP1066 Shows Early Activity in DIPG, a Rare and Difficult-to-Treat Tumor
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Demonstrates Meaningful In Vitro Antiviral Activity Against SARS-CoV-2
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Completes Informative Pre-IND Meeting For STS with Lung Metastases
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q20: Clinical Progress Along Several Lines, Many Shots on Goal
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
More Independent Analysis Affirms Importance of Glycolysis to COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Independent Assessment Confirms In Vitro WP1122 Anti-SARS-CoV-2 Activity
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
In Vivo Preclinical Evidence of WP1066 Efficacy in a Murine Glioma Model
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Evidence of Annamycin Activity in Lung Metastases at AACR
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J